Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)

(2016) Juyong Hong et al.   mAbs

Fc glycans of therapeutic antibodies as critical quality attributes

(2015) Dietmar Reusch et al.   GLYCOBIOLOGY

The choice of mammalian cell host and possibilities for glycosylation engineering

(2014) Michael Butler et al.   CURRENT OPINION IN BIOTECHNOLOGY

Physicochemical characterization of Remsima®

(2014) Soon Kwan Jung et al.   mAbs

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

(2012) Shan Chung et al.   mAbs

Galactosylation variations in marketed therapeutic antibodies

(2012) T. Shantha Raju et al.   mAbs

Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies

(2011) Alfred Schnueriger et al.   MOLECULAR IMMUNOLOGY

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

(2009) Shigeru Iida et al.   BMC CANCER

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

(2008) T Shantha Raju   CURRENT OPINION IN IMMUNOLOGY